Why Invest in Rare Diseases & Orphan Drugs?
In the run-up to Rare Disease Day 2019, David H. Crean, PhD, Managing Director for Objective Capital Partners, reviews the investment and deal activity for orphan drugs in 2018 and delves…
In the run-up to Rare Disease Day 2019, David H. Crean, PhD, Managing Director for Objective Capital Partners, reviews the investment and deal activity for orphan drugs in 2018 and delves…
Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first article for PharmaBoardroom, Durhane explains the changing landscape for access to rare…
Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in innovative biopharmaceutical companies in Canada. I’ve often wondered how things would be if…
After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica Weldon founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from…
It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four…
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she…
The 9th February 2019 marked the launch of the European Medicines Verification System (EMVS) which will use cutting-edge technology to safeguard the medicine supply chain against fake products. Each European country…
The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure clinical compliance, ethical behaviour and the well-being of the nation. The health sector is…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Last week saw the first meeting of the board of Egypt’s new Universal Healthcare Authority (UHA) managed by the Minister of Finance, Mohamed Maait. Created to oversee the implementation of…
See our Cookie Privacy Policy Here
